Amarin Pharma Led ‘Scheme’ to Suppress Competition for Hyperglyceridemia Treatment Vascepa, Class Action Alleges
June 11, 2021 A class action alleges Amarin Pharma, BASF and a number of affiliates have engaged in a scheme to squash generic competition in the United States for Vascepa.